BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36442463)

  • 1. TSAb Modulates Microglia M1 Polarization via Activation of the TSHR-Mediated NF-κB Signaling Pathway.
    Liu Y; Yang H; Wu X; Kuang Y; Ban B; Liang Z; Li L; Huang Z; Lu D; Qin Y; Liang X; Luo Z
    Neuroendocrinology; 2023; 113(4):470-478. PubMed ID: 36442463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
    McLachlan SM; Rapoport B
    Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.
    Mizutori Y; Chen CR; Latrofa F; McLachlan SM; Rapoport B
    J Clin Endocrinol Metab; 2009 Mar; 94(3):927-35. PubMed ID: 19066298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteinyl Leukotriene Receptor 2 is Involved in Inflammation and Neuronal Damage by Mediating Microglia M1/M2 Polarization through NF-κB Pathway.
    Zhao R; Ying M; Gu S; Yin W; Li Y; Yuan H; Fang S; Li M
    Neuroscience; 2019 Dec; 422():99-118. PubMed ID: 31726033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and basic performance verification of a rapid homogeneous bioassay for agonistic antibodies against the thyroid-stimulating hormone receptor.
    Hoshina M; Ojima S; Kawasaki A; Doi K; Ohta S; Inoue A; Murayama H
    J Immunol Methods; 2024 May; 528():113655. PubMed ID: 38447802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxymatrine inhibits neuroinflammation byRegulating M1/M2 polarization in N9 microglia through the TLR4/NF-κB pathway.
    Wang XL; Chen F; Shi H; Zhang M; Yan L; Pei XY; Peng XD
    Int Immunopharmacol; 2021 Nov; 100():108139. PubMed ID: 34517275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C; Morgenthaler NG
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease.
    Kim MR; Faiman C; Hoogwerf BJ; Gupta MK
    Endocr Pract; 1997; 3(6):337-43. PubMed ID: 15251770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sulforaphane reverses Aβ fiber-mediated M1 type microglia polarization and neuroinflammation-mediated necroptosis of neural stem cells by downregulating the MAPK/NF-κB signaling pathways].
    Zhang J; Yang C; Zhang S; Cao T; Peng R; Guo W; Yan Y; Xie S; Peng X; Lü T; Huang T
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Dec; 43(12):2132-2138. PubMed ID: 38189401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible participation of colloid antigen 2 and abhormone (IgG with hormone activity) for the etiology of Graves' disease.
    Ochi Y
    Med Hypotheses; 2019 Jun; 127():23-25. PubMed ID: 31088643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation.
    Allelein S; Diana T; Ehlers M; Kanitz M; Hermsen D; Schott M; Kahaly GJ
    Horm Metab Res; 2019 Jun; 51(6):341-346. PubMed ID: 31207654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells.
    Kamijo K; Nagata A; Sato Y
    Endocr J; 1999 Jun; 46(3):397-403. PubMed ID: 10503992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel hypothesis for the etiology of Graves' disease: TSAb may be thyroid stimulating animal IgG-like hormone and TBAb may be the precursor of TSAb.
    Ochi Y; Kajita Y; Hachiya T; Hamaoki M
    Med Hypotheses; 2012 Jun; 78(6):781-6. PubMed ID: 22472575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.